Effect of Sacubitril/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: A real-world 12-week study

Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

(2020) Boris Bikbov et al.   LANCET

Effect of sacubitril/valsartan on renal function: a systematic review and meta‐analysis of randomized controlled trials

(2020) Francesco Spannella et al.   ESC Heart Failure

Is echocardiography mandatory for patients with chronic kidney disease?

(2019) Emilio Nardi et al.   Internal and Emergency Medicine

Chronic kidney disease, heart failure and neprilysin inhibition

(2019) Richard Haynes et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

(2019) Scott D. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial

(2018) Richard Haynes et al.   CIRCULATION

Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial

(2018) Milton Packer et al.   Lancet Diabetes & Endocrinology

Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure

(2018) Kevin Damman et al.   JACC-Heart Failure

Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study

(2018) Hélène Nougué et al.   EUROPEAN JOURNAL OF HEART FAILURE

Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone

(2016) L. C. W. Roksnoer et al.   CLINICAL SCIENCE

Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis

(2016) Scott D. Solomon et al.   EUROPEAN JOURNAL OF HEART FAILURE

Heart failure and kidney dysfunction: epidemiology, mechanisms and management

(2016) Joerg C. Schefold et al.   Nature Reviews Nephrology

Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis

(2016) Nathan R. Hill et al.   PLoS One

Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?

(2015) Piero Ruggenenti et al.   EUROPEAN JOURNAL OF HEART FAILURE

Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction

(2015) Adriaan A. Voors et al.   EUROPEAN JOURNAL OF HEART FAILURE

LCZ696: a new paradigm for the treatment of heart failure?

(2015) Joan Minguet et al.   EXPERT OPINION ON PHARMACOTHERAPY

Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment

(2014) Kevin Damman et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Spironolactone for Heart Failure with Preserved Ejection Fraction

(2014) Bertram Pitt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

(2014) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β

(2013) Simon J. Henderson et al.   BRAIN

Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis

(2013) K. Damman et al.   EUROPEAN HEART JOURNAL

Influence of Baseline and Worsening Renal Function on Efficacy of Spironolactone in Patients With Severe Heart Failure

(2012) Orly Vardeny et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Mechanisms and Treatment of CKD

(2012) P. Ruggenenti et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Associations between Kidney Function and Subclinical Cardiac Abnormalities in CKD

(2012) M. Park et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

(2012) Scott D Solomon et al.   LANCET

Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction

(2011) Michael R. Zile et al.   CIRCULATION

Cardiac Resynchronization Therapy Reduces Left Atrial Volume and the Risk of Atrial Tachyarrhythmias in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy)

(2011) Andrew Brenyo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts

(2011) Ron T. Gansevoort et al.   KIDNEY INTERNATIONAL

The Cardiorenal Syndrome in Heart Failure

(2011) Kevin Damman et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Relation Between Kidney Function, Proteinuria, and Adverse Outcomes

(2010) Brenda R. Hemmelgarn   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Renal Function and Neurohormonal Changes Following Intravenous Infusions of Nitroglycerin Versus Nesiritide in Patients With Acute Decompensated Heart Failure

(2010) Sheryl L. Chow et al.   JOURNAL OF CARDIAC FAILURE

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

(2010) Luis Miguel Ruilope et al.   LANCET